Tatva Chintan Pharma Chem Limited (NSE:TATVA) Beat Earnings, And Analysts Have Been Reviewing Their Forecasts

Tatva Chintan Pharma Chem Limited (NSE:TATVA) just released its quarterly report and things are looking bullish. Tatva Chintan Pharma Chem delivered a significant beat with revenue hitting ₹1.7b and statutory EPS reaching ₹6.83, both beating estimates by more than 10%. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Following the latest results, Tatva Chintan Pharma Chem's three analysts are now forecasting revenues of ₹6.39b in 2027. This would be a decent 15% improvement in revenue compared to the last 12 months. Per-share earnings are expected to surge 39% to ₹30.50. In the lead-up to this report, the analysts had been modelling revenues of ₹6.38b and earnings per share (EPS) of ₹31.00 in 2027. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

See our latest analysis for Tatva Chintan Pharma Chem

The analysts reconfirmed their price target of ₹1,443, showing that the business is executing well and in line with expectations. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Tatva Chintan Pharma Chem analyst has a price target of ₹1,955 per share, while the most pessimistic values it at ₹835. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.

Of course, another way to look at these forecasts is to place them into context against the industry itself. The analysts are definitely expecting Tatva Chintan Pharma Chem's growth to accelerate, with the forecast 20% annualised growth to the end of 2027 ranking favourably alongside historical growth of 3.1% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 12% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Tatva Chintan Pharma Chem is expected to grow much faster than its industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple Tatva Chintan Pharma Chem analysts - going out to 2029, and you can see them free on our platform here.

It is also worth noting that we have found 1 warning sign for Tatva Chintan Pharma Chem that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.